AUTOLUS THERAPEUTICS PLC Stock Price, News & Analysis

Autolus Therapeutics (Nasdaq: AUTL) announced the appointment of John H. Johnson as non-executive chairman of its Board of Directors, effective September 15, 2021. Johnson, with over 30 years in the life sciences sector, previously held executive roles at Strongbridge Biopharma and major firms like Eli Lilly and Pfizer. The company is preparing for pivotal data on obe-cel, a CD19 CAR T cell therapy aimed at treating adult acute lymphoblastic leukemia, expected in 2022. This leadership change is seen as pivotal for advancing Autolus' clinical programs.

Novaremed AG has acquired Metys Pharmaceuticals AG in an all-share transaction, expanding its pipeline of non-opioid treatments for chronic pain. The acquisition includes two new development projects, allowing Novaremed to target neuropathic pain, including chemotherapy-induced peripheral neuropathy (CIPN). This move aligns with Novaremed's strategy to lead in non-opioid pain management. Additionally, Andrew J. Oakley has been appointed to the Board of Directors, enhancing the leadership team. Key objectives include advancing clinical studies and seeking further capital for development.

Autolus Therapeutics plc (Nasdaq: AUTL) has announced its participation in three upcoming virtual investor conferences. These events include the Goldman Sachs Eleventh Annual Biotech Symposium on September 7, the Wells Fargo Healthcare Conference on September 10 at 7:30 am ET, and the H.C. Wainwright & Co 23rd Annual Global Investment Conference on September 13 at 7:00 am ET. Audiences can access live audio webcasts of the presentations through the company's website, with archived versions available for a limited time.

Autolus is focused on developing innovative T cell therapies to treat various cancers.

Autolus Therapeutics has reported promising results from the Phase 1 ALLCAR19 clinical trial of its CD19 CAR-T therapy, obe-cel, published in the Journal of Clinical Oncology. The therapy is designed to minimize toxicity while enhancing patient response rates in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). Notably, 85% of participants achieved minimal residual disease negative complete responses at one month, and no patients experienced severe cytokine release syndrome. The company plans to advance obe-cel into the pivotal FELIX study to further evaluate its efficacy.

Autolus Therapeutics (Nasdaq: AUTL) announced that its CAR T cell therapy, obe-cel, has received Promising Innovative Medicine (PIM) designation from the UK Medicines and Healthcare products Regulatory Agency (MHRA). This designation acknowledges obe-cel's potential to significantly benefit adult patients with relapsed/refractory B-cell Acute Lymphocytic Leukemia (ALL). The ongoing FELIX Phase 1b/2 study is exploring its efficacy and safety, with promising implications for early access to treatment for patients with high unmet medical needs.

Autolus Therapeutics (Nasdaq: AUTL) reported its Q2 2021 financial results, revealing a net loss of $33.2 million, or $(0.47) per share, an improvement from $(0.62) per share in the prior year. Cash reserves totaled $216.4 million, projected to fund operations into H1 2023. Promising updates on the obe-cel therapy highlighted a 50% event-free survival rate in adult acute lymphoblastic leukemia patients after 24 months and successful outcomes in B-cell non-Hodgkin lymphoma trials. The company anticipates pivotal data from ongoing trials in 2022.

Autolus Therapeutics has entered an exclusive licensing agreement with Moderna for up to four immuno-oncology targets, permitting Moderna to develop and commercialize mRNA therapeutics utilizing Autolus' proprietary binders.

Autolus will receive upfront payments for each licensed target, along with milestone payments for successful commercialization, plus royalties on net sales. This partnership underscores Autolus' innovative positioning in the biopharmaceutical field, particularly in cancer treatment technologies.

Autolus Therapeutics (AUTL) announced the appointment of Dr. Edgar Braendle as Chief Development Officer, effective immediately. His expertise in oncology development is expected to propel the company's lead program, obe-cel, through its pivotal study aimed at treating relapsed/refractory adult Acute Lymphoblastic Leukemia (ALL). Dr. Braendle previously held leadership roles at Sumitomo Dainippon Pharma Oncology and Boston Biomedical. His experience includes managing global oncology programs and a strong background in clinical affairs. Autolus aims to advance its proprietary CAR T cell therapies.

Autolus Therapeutics plc (Nasdaq: AUTL) will release its second quarter 2021 financial results and operational highlights on August 5, 2021, before U.S. market open. A conference call will follow at 8:30 AM EDT to discuss these results. CEO Christian Itin will also participate in a panel discussion on July 14, 2021, at the William Blair Biotech Focus Conference 2021. Autolus specializes in developing advanced programmed T cell therapies for cancer treatment, leveraging proprietary programming technologies for improved efficacy against malignancies.